Provided by Tiger Fintech (Singapore) Pte. Ltd.

Cognition Therapeutics, Inc

0.4474
+0.03247.81%
Post-market: 0.44740.00000.00%19:58 EDT
Volume:370.67K
Turnover:161.14K
Market Cap:18.59M
PE:-0.47
High:0.4484
Open:0.4300
Low:0.4210
Close:0.4150
Loading ...

Life Science Virtual Investor Forum: Presentations Now Available for Online Viewing

GlobeNewswire
·
14 Mar

Cognition Therapeutics to Report Fourth Quarter and Full Year 2024 Results

GlobeNewswire
·
14 Mar

Cognition Therapeutics to Present at Life Sciences Virtual Investor Conference

GlobeNewswire
·
10 Mar

Cognition Therapeutics Publishes Research Supporting the Potential of Zervimesine in Dry AMD

GlobeNewswire
·
27 Feb

Cognition Therapeutics passes pre-defined futility analysis of Phase 2 study

TIPRANKS
·
26 Feb

Cognition VP co-hosting workshop at Neuroimmunology Drug Development Summit

TIPRANKS
·
25 Feb

Cognition Therapeutics’ VP of Research Co-hosting Precision Medicine Workshop at the Neuroimmunology Drug Development Summit

GlobeNewswire
·
25 Feb

Cognition Therapeutics Announces Publication of Commercial Manufacturing Process for Lead Alzheimer’s Candidate, Zervimesine (CT1812)

GlobeNewswire
·
20 Feb

B. Riley Adjusts Cognition Therapeutics Price Target to $2 From $1.50, Maintains Buy Rating

MT Newswires Live
·
06 Feb

Cognition Therapeutics price target raised to $2 from $1.50 at B. Riley

TIPRANKS
·
06 Feb

Director Makes Bold Move with Major Stock Purchase in Cognition Therapeutics

TIPRANKS
·
05 Feb

Cognition’s Positive Phase 2 ‘Shimmer’ Study of Zervimesine (Ct1812) in Dementia With Lewy Bodies (Dlb) Will Be Presented in a Podium Presentation at Ilbdc

THOMSON REUTERS
·
30 Jan

Cognition’s Positive Phase 2 ‘SHIMMER’ Study of Zervimesine (CT1812) in Dementia with Lewy Bodies (DLB) will be Presented in a Podium Presentation at ILBDC

GlobeNewswire
·
30 Jan

Cognition Therapeutics Shows Promising Phase 2 Study Results

TIPRANKS
·
14 Jan

Aspira Women's Health Announces the Appointment of Mike Buhle as SVP of Commercial Operations

ACCESSWIRE
·
10 Jan

B. Riley Upgrades Cognition Therapeutics to Buy From Neutral, Lifts PT to $1.50 From $1

MT Newswires Live
·
19 Dec 2024